Semaglutide faces renewed legal battles as Novo Nordisk targets compounding pharmacies for trademark infringement and false advertising after FDA shortage removal.
Dani Heba
Advertisement
Dani Heba is a summer associate in Hunton’s New York office.
Articles by Dani Heba
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
Dexcom Smart Basal wins FDA Clearance for Type 2 diabetes insulin support
2
Former nursing home CEO sentenced in $146M fraud scheme; AI in the ICU; cannabis in pregnancy – Morning Medical Update
3
Executives guilty in $100M Adderall scheme; California sober; training viruses to fight superbugs – Morning Medical Update
4
U.S. leads in primary care physician burnout among 10 developed nations, study says
5
